Europe needs to be clearer about Covid-19 vaccines
Confusion over blood clot numbers with all four approved Covid-19 vaccines could cause more vaccine hesitancy.
Obfuscation and evasion: Astra shows how not to disclose data
The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.
Does FDA’s plasma nod set a dangerous precedent?
The FDA’s emergency use authorisation for plasma for Covid-19 looks questionable. If this presages an early vaccine nod, we should be very afraid.
Careful label reading reveals more Lynparza doubts
Close analysis of the Parp inhibitor’s pivotal prostate cancer trial raises additional questions over this week’s US approval.
Can Gilead make remdesivir pay?
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
The long path to an effective coronavirus vaccine
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
Rubius confirms the worst
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
Biopharma’s role in tackling coronavirus
The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
Why Novo Nordisk should buy Uniqure
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
